Alps Advisors Inc. Buys Shares of 3,980 TransMedics Group, Inc. $TMDX

Alps Advisors Inc. purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 3,980 shares of the company’s stock, valued at approximately $447,000.

Several other large investors also recently added to or reduced their stakes in the company. Amalgamated Bank lifted its holdings in TransMedics Group by 0.8% during the second quarter. Amalgamated Bank now owns 9,586 shares of the company’s stock valued at $1,285,000 after purchasing an additional 80 shares during the last quarter. Canada Pension Plan Investment Board lifted its stake in shares of TransMedics Group by 2.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock valued at $482,000 after buying an additional 100 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in TransMedics Group by 24.5% in the 2nd quarter. Smartleaf Asset Management LLC now owns 548 shares of the company’s stock worth $72,000 after buying an additional 108 shares during the period. State of Wyoming boosted its holdings in TransMedics Group by 20.9% in the 3rd quarter. State of Wyoming now owns 683 shares of the company’s stock worth $77,000 after buying an additional 118 shares during the period. Finally, TD Waterhouse Canada Inc. grew its stake in TransMedics Group by 26.5% in the 3rd quarter. TD Waterhouse Canada Inc. now owns 601 shares of the company’s stock valued at $69,000 after buying an additional 126 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Insider Buying and Selling

In other news, CFO Gerardo Hernandez sold 920 shares of the stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the transaction, the chief financial officer owned 15,064 shares of the company’s stock, valued at $2,103,235.68. This represents a 5.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Anil P. Ranganath sold 3,000 shares of the firm’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total transaction of $435,660.00. Following the sale, the insider owned 13,955 shares in the company, valued at approximately $2,026,545.10. This trade represents a 17.69% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 8,920 shares of company stock worth $1,257,310. Insiders own 7.00% of the company’s stock.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $129.84 on Friday. The business’s 50-day moving average price is $132.32 and its two-hundred day moving average price is $125.42. TransMedics Group, Inc. has a twelve month low of $62.07 and a twelve month high of $156.00. The stock has a market cap of $4.44 billion, a P/E ratio of 52.57 and a beta of 2.06. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a report on Saturday. Needham & Company LLC raised their target price on TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Canaccord Genuity Group lifted their target price on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Morgan Stanley increased their price target on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $144.25.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.